Loading
A phase 1/2 trial of Adebrelimab and Gemcitabine in pancreatic ductal adenocarcinoma, run by Shanghai Hengrui Pharmaceutical Co., Ltd., now recruiting.
HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors is a phase 1/2 interventional study registered as NCT07296341 by Shanghai Hengrui Pharmaceutical Co., Ltd., with 60 participants planned, started 2026-01-08 and due to reach its primary completion in 2027-10. Interventions recorded: HRS-4642;Adebrelimab Injection; nab-paclitaxel; gemcitabine and HRS-4642;nab-paclitaxel; gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Gemcitabine and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Jiangsu Hengrui Pharmaceuticals, Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/